Abstract
The aim of this work is to study the anti-proliferative potential of two anticancer drugs loaded in nanostructured lipid carriers (NLCs).The maximal inhibition of cell growth by Raloxifene (RLX) & Curcumin (CUM) nanostructured lipid carriers (RLX-CUM-NLCs) was determined by assessing the viability of MDA-MB 231 cells. As far as we know, this is the first research to look at the effects of RLX-CUM-NLCs on DMBA-induced breast carcinogenesis in a rat model. RLX-CUM-NLCs reduced the number of tumors in an in-vivo investigation. After 14 weeks of induction, we discovered a tumor with a 100% incidence rate. The incidence of experimental breast cancer was decreased to 83.33% in the RLX-treated group. In contrast, RLX-CUM-NLCs demonstrated a significant anticancer effect with a 50% incidence in the RLX-CUM-NLCs group. Compared to controls, the RLX-CUM-NLCs therapy did not cause any toxicity in the animals in terms of food intake, body weight, or activity levels until 300 mg/kg BW. The current research shows that the RLX-CUM-NLCs has a chemopreventive impact on DMBA-induced breast cancer in rats by decreasing tumor burden and restoring marker enzymes activity.
Highlights
Breast cancer is the most often diagnosed cancer in women and the leading cause of death
The results revealed that FA-CUM-nanostructured lipid carriers (NLCs) were efficient in selective delivery to cancer cells over expressing FA receptors (FRs)
In vitro cytotoxic effect of RLX, CUM and RLXCUM-NLC studied on MDA-MB-231 by MTT assay after 24 h of exposure showed that RLX, CUM and RLX-CUM-NLC produced dosedependent decrease in the percentage viability of the cells (Figs. 1-3) [18]
Summary
Breast cancer is the most often diagnosed cancer in women and the leading cause of death. The lipid re-arranges into less stable forms when it is molten and cool during the synthesis of SLNs: polymorphic shape and form. These lipids are amorphous, which allows medicines to be retained inside the lipid matrix [6]. Liquid lipids contributed in widening the loading capabilities of lipid nanocarriers by increasing the number of defects wherein amorphous drug clusters might fit [9]. As a consequence, this dual lipid framework may be able to accommodate higher drug load, but it may be able to reduce drugs expulsion from lipid during storage [10]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
